News & Analysis on Clinical Trial Services & Contract Research And Development
Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...
The temporary medicines unit built for the agency's Central Intravenous Additive Service can produce up to 2,600 syringes weekly to meet growing demand
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.